Citigroup
CSTL icon

Citigroup’s Castle Biosciences CSTL Stock Holding History

Citigroup’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$98.9K Sell
4,027
-28,395
-88% -$930K ﹤0.01% 4289
2025
Q4 		$1.26M Buy
32,422
+28,172
+663% +$908K ﹤0.01% 2983
2025
Q3 		$96.8K Sell
4,250
-9,822
-70% -$200K ﹤0.01% 4278
2025
Q2 		$287K Sell
14,072
-48,629
-78% -$900K ﹤0.01% 3899
2025
Q1 		$1.26M Buy
62,701
+21,374
+52% +$529K ﹤0.01% 3089
2024
Q4 		$1.1M Buy
41,327
+15,748
+62% +$480K ﹤0.01% 3289
2024
Q3 		$730K Sell
25,579
-42,655
-63% -$1.09M ﹤0.01% 3494
2024
Q2 		$1.49M Buy
68,234
+61,580
+925% +$1.37M ﹤0.01% 2589
2024
Q1 		$147K Buy
6,654
+1,069
+19% +$23.3K ﹤0.01% 4142
2023
Q4 		$121K Buy
5,585
+2,855
+105% +$50.2K ﹤0.01% 4123
2023
Q3 		$46.1K Sell
2,730
-8,443
-76% -$148K ﹤0.01% 4166
2023
Q2 		$153K Buy
11,173
+8,427
+307% +$171K ﹤0.01% 4023
2023
Q1 		$62.4K Sell
2,746
-726
-21% -$17.7K ﹤0.01% 4198
2022
Q4 		$81.7K Sell
3,472
-83,501
-96% -$1.94M ﹤0.01% 4099
2022
Q3 		$2.27M Sell
86,973
-45,964
-35% -$1.29M ﹤0.01% 2056
2022
Q2 		$2.92M Buy
132,937
+124,294
+1,438% +$2.89M ﹤0.01% 1841
2022
Q1 		$388K Sell
8,643
-5,924
-41% -$245K ﹤0.01% 3672
2021
Q4 		$624K Sell
14,567
-1,061
-7% -$55.4K ﹤0.01% 3645
2021
Q3 		$1.04M Buy
15,628
+1,918
+14% +$135K ﹤0.01% 3052
2021
Q2 		$1M Buy
13,710
+11,993
+698% +$792K ﹤0.01% 3221
2021
Q1 		$118K Sell
1,717
-1,923
-53% -$145K ﹤0.01% 4281
2020
Q4 		$244K Buy
3,640
+1,778
+95% +$96.4K ﹤0.01% 4841
2020
Q3 		$96K Sell
1,862
-2,588
-58% -$115K ﹤0.01% 5150
2020
Q2 		$168K Buy
4,450
+665
+18% +$22.7K ﹤0.01% 5155
2020
Q1 		$113K Buy
3,785
+1,707
+82% +$51.5K ﹤0.01% 5246
2019
Q4 		$71K Buy
2,078
+1,915
+1,175% +$46.8K ﹤0.01% 6039
2019
Q3 		$3K Buy
+163
New +$3.61K ﹤0.01% 7446

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup's CSTL Position: Q1 2026 in Review

Citigroup reduced its Castle Biosciences (CSTL) stake by 88% in Q1 2026, selling an estimated $930K and leaving 4,027 shares worth $98.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4289.

Citigroup first reported a position in CSTL in Q3 2019 and has held it in 27 quarters since. The position peaked at $2.92M in Q2 2022. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Citigroup held 4,027 shares of Castle Biosciences worth $98.9K as of Q1 2026.
  • Citigroup sold 28,395 Castle Biosciences shares in Q1 2026, an estimated $930K.
  • Castle Biosciences made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4289 holding.
  • Citigroup first reported a position in Castle Biosciences in Q3 2019 and has held it in 27 quarters since.
  • Citigroup's Castle Biosciences position peaked at $2.92M in Q2 2022.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.